Sarepta Therapeutics Inc (SRPT) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of Sarepta Therapeutics Inc stock $15.45, price $14.77, upside +4.6%, quality 33 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Sarepta Therapeutics Inc
SRPT · USThe stock is already about fairly priced, weak company and price moving sideways: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $11.93 – $163.85 · fair‑value band $11.58 – $19.31 · the $14.77 price screens below the $15.45 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Sarepta Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.
Show moreShow less
It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials.
It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Stock analysis
Sarepta Therapeutics Inc (SRPT) currently trades at $14.77, while our estimate is $15.45, so the stock looks roughly fairly valued today (gap 4.4%).
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $11.58 (bear) to $19.31 (bull), the price of $14.77 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Sarepta Therapeutics Inc reported revenue of $2.2B in FY2025 versus $702M in FY2021, a compound +33.0%/yr. Reported net income was −$713M in FY2025.
Key figures
Market cap $1.6B Small · P/S ratio 0.95 · EPS (TTM) $0.0200 · Net margin −32.5% · Return on equity −8.1% · Return on assets (EBIT) −10.8% (5-year average) · Operating margin −2.4% · Revenue (TTM) $2.0B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (low confidence).
What moves the price
The share trades about 38% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 5%, SRPT screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
- SaleStephen MayoDirector7,239 shares at $17.02$123,208Mar 12, 2026
- SaleIan Michael EstepanChief Operating Officer13,187 shares at $22.31$294,202Dec 16, 2025
Plus 13 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Watch SRPT, get fair value alerts →
Earlier news
- Ultragenyx (RARE) vs. SRPT and BMRN: Can Upcoming Drug Approvals Unlock the Next Phase of Biotech Growth?
- Sarepta Therapeutics (SRPT) Earnings Preview Puts Its Fair Value Back In Focus
- Global Gene Silencing Therapeutics Market Report 2026-2030 | Capitalize on 16.3% CAGR as Novartis, Alnylam, Ionis, Sarepta, and Arrowhead Ac
- Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?
Compare Sarepta Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Dividend yield by industry
- EV/EBITDA by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $957.76 | $1,275 | +33% | vs SRPT |
| Vertex Pharmaceuticals Incorporated VRTX | $534.20 | $592.46 | +11% | vs SRPT |
| Samsung Biologics Co 207940 | 1,414,000 KRW | 1,552,100 KRW | +10% | vs SRPT |
| argenx SE ARGX | $947.52 | $908.40 | −4% | vs SRPT |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs SRPT |
| Moderna, Inc MRNA | $206.80 | $135.64 | −34% | vs SRPT |
| BeOne Medicines AG 6160 | HK$247.40 | HK$152.92 | −38% | vs SRPT |
| Revolution Medicines, Inc RVMD | $162.69 | $88.78 | −45% | vs SRPT |
| Celltrion, Inc 068270 | 213,000 KRW | 74,945 KRW | −65% | vs SRPT |
| Royalty Pharma plc RPRX | $68.68 | $19.01 | −72% | vs SRPT |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Sarepta Therapeutics Inc (SRPT) overvalued or undervalued?
What is the fair value of SRPT?
What is the quality score of SRPT?
What is the price target for Sarepta Therapeutics Inc (SRPT)?
What is the Sarepta Therapeutics Inc stock forecast for 2026?
What is the revenue of Sarepta Therapeutics Inc (SRPT)?
What is the intrinsic value of Sarepta Therapeutics Inc (SRPT)?
Is Sarepta Therapeutics Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of SRPT?
How much is Sarepta Therapeutics Inc worth?
What do the bullish and bearish scenarios say about SRPT?
What is the PEG ratio of SRPT?
How solid is the balance sheet of Sarepta Therapeutics Inc (SRPT)?
How far is SRPT from its 52-week high?
Which stocks are comparable to Sarepta Therapeutics Inc?
Is Sarepta Therapeutics Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Sarepta Therapeutics Inc (SRPT)?
What should I pay attention to with Sarepta Therapeutics Inc right now?
Key figures of Sarepta Therapeutics Inc
How large is the market capitalisation of Sarepta Therapeutics Inc (SRPT)?
What is the P/S ratio of Sarepta Therapeutics Inc (SRPT)?
What are the earnings per share of Sarepta Therapeutics Inc (SRPT)?
What is the net margin of Sarepta Therapeutics Inc (SRPT)?
What is the return on equity of Sarepta Therapeutics Inc (SRPT)?
What is the EBIT return on assets of Sarepta Therapeutics Inc (SRPT)?
What is the operating margin of Sarepta Therapeutics Inc (SRPT)?
How fast is revenue growing at Sarepta Therapeutics Inc (SRPT)?
How fast are earnings growing at Sarepta Therapeutics Inc (SRPT)?
How much free cash flow does Sarepta Therapeutics Inc (SRPT) generate?
How much net debt does Sarepta Therapeutics Inc (SRPT) carry?
Watch Sarepta Therapeutics Inc in the live analysis
One click puts Sarepta Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.